Q-omics provides the consensus-scored DDX4 profile across patient tissues and cancer cell-line models. DDX4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DDX4 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, DDX4 RNA expression shows 14,033 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where DDX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX4 survival associations across molecular data types. DDX4 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX4 RNA expression–survival associations across cancer types. High DDX4 expression shows unfavorable associations in KIRC, CHOL, UVM and KIRP, but favorable associations in UCS and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DDX4 RNA expression.
This table summarizes DDX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for DDX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX4 shows lower tumor expression in KICH and KIRP and higher tumor expression in LUAD, LIHC, CHOL and BLCA. The LUAD box plot shows higher DDX4 RNA expression in tumor versus normal tissue (log2 FC = +0.096, t-test p = .004).
This table shows molecular features associated with DDX4 in patient tissues and cancer cell lines. In patient samples, DDX4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DDX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
